Research Article

Protective and Therapeutic Effects of Beta Glucan Administration on Experimental Ulcerative Colitis Model Induced by TNBS

Volume: 23 Number: 3 December 30, 2021
EN TR

Protective and Therapeutic Effects of Beta Glucan Administration on Experimental Ulcerative Colitis Model Induced by TNBS

Abstract

Aim: In this study, it was aimed to investigate the effects of beta glucan (BG) on the experimental colitis model created by using trinitrobenzene sulfonic acid (TNBS). Material and Methods: Thirty-two Wistar Albino rats were divided equally into four groups as sham control, TNBS, TNBS-BG3, and TNBS-BG10 groups. While saline was administrated to sham group, TNBS was administered intrarectally to the TNBS groups under anesthesia. BG was administered at a dose of 100 mg/kg by oral gavage, intragastrically, for 3 days (TNBS+3) to the TNBS-BG3 group and for 10 days (7+TNBS+3) to the TNBS-BG10 group. At the end of the study, macroscopic, histological and biochemical tests were applied to the colon tissues taken. Results: It was determined by histopathological scoring and biochemical results that BG administration caused positive effects on colon damage due to colitis. Malondialdehyde level and myeloperoxidase activity were found to be significantly higher in the TNBS group compared to the other groups (p=0.003 and p<0.001, respectively). Antioxidant levels increased in BG treated groups compared to TNBS group. While this increase was statistically significant among glutathione levels (p<0.001), it was not statistically significant in catalase enzyme activity (p=0.218). BG administration reduced the increase in lipid peroxidation and leukocyte infiltration level in the colon tissue. Positive changes due to the prophylactic effect of BG were determined in histological and biochemical results. Conclusion: BG administration has been found to show anti-inflammatory and antioxidant properties, and BG has a treatment potential in reducing colon tissue damage due to TNBS-induced colitis.

Keywords

Supporting Institution

Aydin Adnan Menderes University, Scientific Research Projects Committee

Project Number

TPF-13021

References

  1. Petronis A, Petroniene R. Epigenetics of inflammatory bowel disease. Gut. 2000;47(2):302-6.
  2. Gasche C, Scholmerich J, Brynskov J, D’Haens G, Hanauer SB, Irvine EJ, et al. A simple classification of Crohn’s disease: report of the Working Party for the World Congresses of Gastroenterology, Vienna 1998. Inflamm Bowel Dis. 2000;6(1):8-15.
  3. Norris AA, Lewis AJ, Zeitlin IJ. Changes in colonic tissue levels of inflammatory mediators in a guinea-pig model of immune colitis. Agents Actions. 1982;12(1-2):243-6.
  4. Selve N. Chronic intrajejunal TNBS application in TNBS-sensitized rats: a new model of chronic inflammatory bowel diseases. Agents Actions. 1992;Spec No:C15-7.
  5. Podolsky D. Inflamatory bowel disease. N Engl J Med. 2002;347(6):417-29.
  6. Ordás I, Eckmann L, Talamini M, Baumgart DC, Sandborn WJ. Ulcerative colitis. Lancet 2012;380(9853):1606-19.
  7. Kaser A, Zeissig S, Blumberg RS. Inflammatory bowel disease. Annu Rev Immunol. 2010;28:573-621.
  8. Grisham MB, Granger DN. Neutrophil-mediated mucosal injury. Role of reactive oxygen metabolites. Dig Dis Sci. 1988;33(3 Suppl):6S-15S.

Details

Primary Language

English

Subjects

Clinical Sciences

Journal Section

Research Article

Publication Date

December 30, 2021

Submission Date

September 5, 2021

Acceptance Date

November 18, 2021

Published in Issue

Year 2021 Volume: 23 Number: 3

APA
Tokmak, D., Şirinyıldız, F., & Ek, R. O. (2021). Protective and Therapeutic Effects of Beta Glucan Administration on Experimental Ulcerative Colitis Model Induced by TNBS. Duzce Medical Journal, 23(3), 276-281. https://doi.org/10.18678/dtfd.991389
AMA
1.Tokmak D, Şirinyıldız F, Ek RO. Protective and Therapeutic Effects of Beta Glucan Administration on Experimental Ulcerative Colitis Model Induced by TNBS. Duzce Med J. 2021;23(3):276-281. doi:10.18678/dtfd.991389
Chicago
Tokmak, Deren, Ferhat Şirinyıldız, and Rauf Onur Ek. 2021. “Protective and Therapeutic Effects of Beta Glucan Administration on Experimental Ulcerative Colitis Model Induced by TNBS”. Duzce Medical Journal 23 (3): 276-81. https://doi.org/10.18678/dtfd.991389.
EndNote
Tokmak D, Şirinyıldız F, Ek RO (December 1, 2021) Protective and Therapeutic Effects of Beta Glucan Administration on Experimental Ulcerative Colitis Model Induced by TNBS. Duzce Medical Journal 23 3 276–281.
IEEE
[1]D. Tokmak, F. Şirinyıldız, and R. O. Ek, “Protective and Therapeutic Effects of Beta Glucan Administration on Experimental Ulcerative Colitis Model Induced by TNBS”, Duzce Med J, vol. 23, no. 3, pp. 276–281, Dec. 2021, doi: 10.18678/dtfd.991389.
ISNAD
Tokmak, Deren - Şirinyıldız, Ferhat - Ek, Rauf Onur. “Protective and Therapeutic Effects of Beta Glucan Administration on Experimental Ulcerative Colitis Model Induced by TNBS”. Duzce Medical Journal 23/3 (December 1, 2021): 276-281. https://doi.org/10.18678/dtfd.991389.
JAMA
1.Tokmak D, Şirinyıldız F, Ek RO. Protective and Therapeutic Effects of Beta Glucan Administration on Experimental Ulcerative Colitis Model Induced by TNBS. Duzce Med J. 2021;23:276–281.
MLA
Tokmak, Deren, et al. “Protective and Therapeutic Effects of Beta Glucan Administration on Experimental Ulcerative Colitis Model Induced by TNBS”. Duzce Medical Journal, vol. 23, no. 3, Dec. 2021, pp. 276-81, doi:10.18678/dtfd.991389.
Vancouver
1.Deren Tokmak, Ferhat Şirinyıldız, Rauf Onur Ek. Protective and Therapeutic Effects of Beta Glucan Administration on Experimental Ulcerative Colitis Model Induced by TNBS. Duzce Med J. 2021 Dec. 1;23(3):276-81. doi:10.18678/dtfd.991389